

Antimicrobial Susceptibility Test Results for Gram-positive isolates recovered from all sites: 2024

Organism Name	Antibiotics in common use (1st line reporting)											Reserved	Topical
	Number tested	Ampicillin/ amoxicillin	Penicillin	Meth/Flucloxacillin	Erythromycin	Clindamycin #	Gentamicin	Nitrofurantoin ^d	Trimethoprim ^d	Trimethoprim+sulfamethoxazole	Vancomycin #	Ciprofloxacin #	Chloramphenicol
<i>S. aureus</i> (not MRSA)	631		15	100 ^a	93	94	99			99		93	100
MRSA *	20		0	0	84	89	88			95			
<i>S. saprophyticus</i>	34	100		100				100	100	100			
<i>Enterococcus faecalis/spp</i> ^b	121	98						97			99		
<i>Streptococcus pneumoniae</i> *	18	100			80	83				70			
<i>Enterococcus faecium</i>	3												
<i>Streptococcus</i> GrpA	5												

1 x VRE

Antimicrobial Susceptibility Test Results for Gram-negative isolates recovered from all sites: 2024

Organism Name	Antibiotics in common use (1st line reporting)										Reserved (2nd line reporting)			
	Number tested	Ampicillin/ amoxicillin	Amoxicillin-Clavulanate	Cefuroxime IV	Cefalexin ^d	Gentamicin	Nitrofurantoin ^d	Trimethoprim ^d	Trimethoprim+sulfamethoxazole	Tetracycline	Ceftriaxone	Ciprofloxacin [#]	Meropenem [#]	Piperacillin-Tazobactam ^{\$}
<i>Escherichia coli</i>	696	63	69		95	96	99	84	92		97	90	100	98
<i>ESCM group</i>	49	0	0		0	100		92	93		94	97	100	96
<i>Klebsiella oxytoca</i> [*] (ex. 1x CRE)	20	0	85		88	100		100	100		90	96		
<i>Klebsiella pneumoniae</i>	54	0	78		94	100		90	90		94	95	100	96
<i>Proteus mirabilis</i>	40	85	98		100	100		64	84		100	100	100	100

West Coast Hospital

<i>Haemophilus influenzae</i>	68	50	84	77		57	100
<i>Pseudomonas aeruginosa</i>	46						
ESCM group: <i>Enterobacter spp</i> , <i>Serratia marcescens</i> , <i>Citrobacter spp</i> , <i>Morganella morganii</i>							

	96	91	100

* Tested on 10- 30 isolates

^a *S. aureus* susceptible to methicillin/flucloxacillin denotes susceptibility to cefazolin and amoxicillin-clavulanate

^b Enterococcus species are intrinsically resistant to cephalosporins

^c Includes Intermediate (Susceptible, Increased Exposure) results

^d Treatment of uncomplicated urinary tract infections only

Use requires patient-specific Infectious Diseases/Clinical Microbiology approval (document this in the clinical notes) unless following a CDHB antimicrobial guideline e.g. 'The Pink Book'.

\$ Use requires patient-specific Infectious Diseases/Clinical Microbiology/Respiratory Specialist approval (document this in the clinical notes) unless following a CDHB antimicrobial guideline e.g. 'The Pink Book'.

No data or not tested
Colour Interpretation
≥ 90% Susceptible
70 - 89% Susceptible
< 70% Susceptible